All In Biotech

Drug Trial Radar · NCT06293417

To Assess With Ezefeno Tab. in Patients With Dyslipidemia and T2DM

To Assess the Long-term Efficacy and Safety of Combined Therapy With Ezefeno Tab. in Patients With Dyslipidemia Who do Not Achieve Adequate Control of Non-HDL-C Levels Even With Moderate-intensity Monotherapy

Last checked: Nov 20, 2026Latest source record: Aug 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 3,958 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

3,958

Planned (sponsor's estimate)

Start

Mar 1, 2024

Primary completion

Feb 1, 2027

Study completion Feb 1, 2027

Sponsor

Lead sponsor
Korea University Anam HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 5, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this Randomized controlled trials is to assess in the long term efficacy and safety of ezefeno. The primary endpoint are: * major adverse cardiovascular events within 48 months of the trial duration * microvascular events within 48 months of the trial duration

Conditions

  • T2DM (Type 2 Diabetes Mellitus)
  • Dyslipidemias

Interventions

  • Ezetimibe/fenofibrate (Ezefeno) and moderate-intensity statinDrug

    Treatment group

  • Dose escalation of moderate-intensity statinDrug

    Control group

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. major adverse cardiovascular events and diabetic microvascular events for 48 monthsTime frame: 48month from baseline

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Korea University Anam Hospital

    Seoul, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.